David Mazzo

NeoStem Inc (NASDAQ: NBS) recently received a grant of $17.7 million to fund the company's effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent. NeoStem CEO...